ESSA Pharma Inc (EPIX) has released an update.
The Company announced new dose escalation data from its Phase 1/2 study of Masofaniten in combination with enzalutamide for treatment in a press release on January 25, 2024, presented at the 2024 ASCO Genitourinary Cancers Symposium.
For further insights into EPIX stock, check out TipRanks’ Stock Analysis page.
